Breaking News

FTC’s new approach puts PBMs in the crosshairs; Biden Covid adviser David Kessler to exit

 

 

Daily Recap

Submit your application here to be considered for the 2023 STAT Madness, a bracket-style tournament to find the best innovations in science and medicine. Nominations close this Tuesday.

STAT+: With the FTC's more expansive approach to antitrust, PBMs are in the crosshairs

By John Wilkerson

SAUL LOEB/POOL/AFP via Getty Images

The FTC is hoping to expand its authority to crack down on unfair business practices, a shift that has implications for its scrutiny of PBMs.

Read More

Biden Covid adviser David Kessler to exit as pandemic response winds down

By Sarah Owermohle

Susan Walsh-Pool/Getty Images

David Kessler, the D.C. veteran who guided dispatches of millions of Covid vaccines and treatments, is exiting the Biden administration.

Read More

STAT+: As Ginkgo stock sinks, CEO Jason Kelly tries to win over drugmakers in San Francisco

By Jason Mast and Matthew Herper

Ruby Wallau/STAT

Under pressure, the CEO has been meeting with dozens of drugmakers in San Francisco to find partners for his synthetic biology platform.

Read More

STAT+: Biotech startups are hungry for dollars. Here's what one pharma executive was looking for at JPM

By Allison DeAngelis

Courtesy Bayer

The balance of power between biotech startups and big pharma has shifted — but Bayer executive Marianne De Backer is still looking for deals.

Read More

Opinion: For addiction treatment, longer is better. But insurance companies usually cut it short

By Nick Hayes

Business Wire

Longer engagement is a key to successful addiction treatment. Yet insurance companies tend to approve only short periods of treatment.

Read More

STAT+: Congressional Medicare advisers warn of higher drug prices, despite new price negotiation

By John Wilkerson

Adobe

The new law directing Medicare to negotiate drug prices may actually increase prices for new drugs, congressional Medicare advisers said.

Read More

STAT+: Q&A with Carbon Health's Myoung Cha: Why the company is changing course

By Mohana Ravindranath

AP/Business Wire

Carbon Health is in a turbulent time: The primary care tech company has had layoffs and announced plans to dial back major business lines.

Read More

STAT+: Oscar Health's CEO on post-hype health insurance and finally turning a profit

By Bob Herman

Noam Galai/Getty Images

“Profitability is the number one goal” for this year, Oscar CEO Mario Schlosser told STAT in an interview at #JPM23.

Read More

Friday, January 13, 2023

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2023, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments